Clinical Trial Update: Phase 1 Study to Assess Safety and Efficacy of ANG003 [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating ANG003 for Exocrine Pancreatic Insufficiency has completed, assessing safety and preliminary efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exocrine Pancreatic Insufficiency

Drugs mentioned

• ANG003

Snippet

Sponsor: Anagram Therapeutics, Inc. | Conditions: Exocrine Pancreatic Insufficiency | Phase 1 | Status: COMPLETED